Immunome (NASDAQ:IMNM) Posts Quarterly Earnings Results, Misses Estimates By $0.15 EPS

Immunome (NASDAQ:IMNM) released its quarterly earnings data on Monday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.15), FiscalAI reports.

Immunome Stock Performance

Shares of IMNM stock traded up $0.65 on Monday, hitting $19.36. The company had a trading volume of 1,376,707 shares, compared to its average volume of 1,380,800. The firm has a market cap of $2.20 billion, a P/E ratio of -7.65 and a beta of 2.68. The stock’s 50-day moving average is $21.49 and its two-hundred day moving average is $22.40. Immunome has a twelve month low of $15.46 and a twelve month high of $30.06.

Analyst Ratings Changes

Several research firms recently commented on IMNM. Wall Street Zen downgraded shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Truist Financial upped their price target on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. William Blair began coverage on shares of Immunome in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Thursday, October 15th. Finally, Stifel Nicolaus began coverage on shares of Immunome in a research note on Wednesday, September 30th. They set a “hold” rating and a $24.00 price target for the company. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Immunome currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.25.

Insider Transactions at Immunome

In other news, Director Isaac Barchas sold 62,291 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $26.23, for a total transaction of $1,633,892.93. Following the completion of the transaction, the director directly owned 92,211 shares in the company, valued at $2,418,694.53. This trade represents a 40.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 13,200 shares of Immunome stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the completion of the transaction, the insider directly owned 65,050 shares in the company, valued at approximately $1,647,066. This represents a 16.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 86,539 shares of company stock valued at $2,269,175 over the last 90 days. 7.21% of the stock is owned by corporate insiders.

Immunome Company Profile

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need.

The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.

Immunome became a publicly traded company in 2023 following a merger with Morphimmune and a combination with Ayala Pharmaceuticals.